tbuckley/cabot-search huggingface dataset:
CONGENITAL SYPHILIS OF THE STOMACH
Authors: H S MITCHELL
Journal: Annals of Internal Medicine (1954)

Case Reports1 February 1954CONGENITAL SYPHILIS OF THE STOMACHH. S. MITCHELL, M.D.H. S. MITCHELL, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-40-2-369 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTertiary syphilis of the stomach has always been a rather uncommon finding. Estimates of incidence vary from 0.1 per cent of syphilitic patients (Chase, quoted by Eusterman) to 4 per cent of gastric resections (Ayoma).3Eusterman in 19311reported 93 cases. Harris and Youmans2suggested that the following points should be met to provide a reasonably conclusive diagnosis of syphilis: (1) evidence of organic disease of the stomach, which on x-ray examination is indistinguishable from carcinoma; (2) a comparatively young individual; (3) the presence of other evidence of syphilis; (4) a qualified improvement under antisyphilitic treatment; (5) in cases operated...Bibliography1. Eusterman GB: Syphilis of the stomach, in Portis, S. A.: Diseases of the digestive system, 1944, Lea & Febiger, Philadelphia, pp. 290-301. Google Scholar2. HarrisYoumans SJB: Syphilis of the stomach, South. M. J. 24: 847-855 (Oct.) 1931. CrossrefGoogle Scholar3. Bockus HL: Gastroenterology, 1943-46, W. B. Saunders Company, Philadelphia. Google Scholar4. Verbrycke JR: Congenital syphilis of the stomach, Am. J. Syph. 13: 524-526 (Oct.) 1929. Google Scholar5. Marcus JM: Syphilis of the stomach, M. Clin. North America 9: 717, 1925. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Montreal, Canada*Received for publication July 10, 1953. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLocalized lesions of the stomach in childrenDie Erkrankungen des Magens und ZwölffingerdarmesSecretory and Histologic Changes after Treatment of Gastric Syphilis 1 February 1954Volume 40, Issue 2Page: 369-374KeywordsCongenital syphilisStomachSyphilis ePublished: 1 December 2008 Issue Published: 1 February 1954 PDF downloadLoading ...
1037. Site-Specific Genomic Integration in Hematopoietic Cells
Authors: Roger P. Hollis, Sarah Nightingale, Michele P. Calos, Donald B. Kohn
Journal: Molecular Therapy (2004)

Methods of gene transfer to hematopoietic stem cells (HSCs) that result in safe stable chromosomal integration and persistent gene expression in vivo are desired. HSC are an attractive target as their modification could provide treatments for many inherited blood diseases such as Severe Combined Immunodeficiency (SCID) and acquired diseases such as infection by Human Immunodeficiency Virus (HIV-1). PhiC31 integrase is a site-specific recombinase that catalyses a specific, unidirectional integration reaction between two distinct DNA sites known as attB and attP. It has been demonstrated previously that a plasmid expressing the integrase can mediate the integration of a co-delivered attB-containing plasmid into mammalian chromosomes at pseudo attP-sites (host sites sharing homology to attP, as recognized by phiC31). Here we delivered the non-viral phiC31 integrase system to achieve site-restricted integration of genes into the genome of hematopoietic cells using the AMAXA nucleoporator. We applied the phiC31system to integrate a MND-driven eGFP reporter gene into the genomes of human hematopoietic cell lines and primary CD34+ progenitor cells. In the K562 cell line, we observed stable expression of eGFP in >60% of cells for over 2 months; in contrast, in control cells not treated with integrase, the level of gene expression had fallen to near background (<1%) by 2 weeks. In purified human cord blood and bone marrow CD34+ progenitor cells, the integrase repeatedly improved marking efficiency when compared to controls. However, to date relatively low levels of cells that express eGFP (1% range) have been observed over 4-6 weeks of long-term culture. A LAM-PCR based method was applied to investigate pseudo attP-sites in the marked hematopoietic cells. Analyses of integration sites in these marked cells indicated that the preferred pseudo attP-sites chosen by the phiC31 integrase in hematopoietic cells may differ from those previously reported in other commonly used human cell lines and primary cells. Integration events into these pseudo attP-sites are directly responsible for the high level of marking seen in these hematopoietic studies. We are currently defining the identity and expression context afforded by hematopoietic-preferred integration sites. These encouraging results of long-term stable expression highlight the potential of this likely safer non-viral method for ameliorating diseases affecting the hematopoietic system.
Abstract 17792: Impaired Efficacy of Bone Marrow Cell Therapy for Myocardial Infarction Reflects Decreasing Bone Marrow B Cells with Advancing Age
Authors: Songtao An, Xiaoyin Wang, Melissa A Ruck, Dmitry S Kostyushev, Monika Varga, Sergey V Suchkov, Scott Kogan, Michelle L Hermiston, Matthew L Springer
Journal: Circulation (2014)

Introduction:  Implantation of unfractionated bone marrow cells (BMCs) into mouse hearts post-myocardial infarction (MI) can prevent a decline in cardiac function. However, clinical trials of BMC therapy have been less successful. While most mouse experiments use young healthy BMC donors, MI patients undergoing autologous cell therapy (i.e., receiving their own BMCs) are older and are post-MI. We reported previously that BMCs from old mice, or from mice that are themselves post-MI, are impaired in this therapeutic capacity; and that inflammation caused by donor MI mediates impairment of BMC therapeutic potential. As an indication of ongoing inflammation, we reported reduced levels of B cells in post-MI BMCs.   Hypothesis:  Because B cells have been reported to be a therapeutic subpopulation of BMCs, we asked whether B cell changes in bone marrow may account for the reduced therapeutic potential of BMCs from post-MI and/or aged donors.   Methods:  We induced permanent coronary artery ligation MI, and injected 10 6  BMCs per heart by ultrasound guidance into the infarct border zone 3 days post-MI. Recipient mice were always young (10-12 weeks) while BMC donors varied in age. Echocardiography was performed before MI, 2 days post-MI (the day before injection), and 28 days post-MI.   Results:  Injection of BMCs from donors of increasing ages (10 weeks, 6 months, and 1, 1.5, and 2 years) resulted in progressively lower day 28 recipient left ventricular ejection fraction (EF; Fig. 1a); and larger end systolic and diastolic chamber volumes, lower wall thickness, and larger infarct size (not shown). FACS analysis revealed fewer B cells in aged donor BMCs (Fig. 1b). Young healthy donor BMCs became less therapeutic when manually depleted of B cells (Fig. 1c).   Conclusions:  Donor age or MI lowers the number of bone marrow B cells, resulting in a less therapeutic BMC population. Our findings may partially explain why clinical trials of BMC therapy for MI have led to more modest results than mouse studies.
Endoglin(CD105) is an effective target for an oral DNA vaccine against breast cancer
Authors: Sung-Hyung Lee, Noriko Mizutani, Yunping Luo, He Zhou, Rong Xiang, Ralph A. Reisfeld
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

6175 

Growth and survival of breast tumor cells is well known to require angiogenesis, i.e., new blood vessel formation by proliferating endothelial cells. Expression of endoglin (CD105), a co-receptor of the TGF-beta receptor complex, is markedly enhanced on proliferating endothelial cells within the breast tumor microenvironments. Although CD105 is known to play an important role in regulating the survival of proliferating endothelial cells, its role as a target for DNA vaccines has not been extensively investigated. Thus, we established experimental systems to examine 1) the extent of anti-angiogenic/anti-tumor effects achieved with an oral DNA vaccine encoding murine CD105 carried by double attenuated (Dam-, AroA-) Salmonella typhimurium to secondary lymphoid organs, i.e., Peyer’s Patches, and 2) determine whether the knock-down of CD105 on highly metastatic murine 4T1 breast tumor cells achieved by specific siRNA affects their invasive and migratory characteristics. We demonstrate here that the breast carcinoma cell line, 4T1 strongly expresses endoglin on the cell surface, whereas another breast carcinoma cell line, D2F2 does not. However, even though the D2F2 cell line does not express endoglin, we found that in vivo proliferating endothelial cells within the D2F2 tumor microenvironment strongly express it. In fact, BALB/C mice immunized with a DNA vaccine encoding endoglin and co-expressing secretory chemokine CCL21 effectively suppressed D2F2 pulmonary metastases when compared to mice vaccinated with either endoglin or CCL21. In addition, D2F2 target cells stably transfected with endoglin were more sensitive to CTL killing than non-expressors. These results suggest that a DNA vaccine encoding both endoglin and secretory CCL21 is effective in inducing T-cell mediated immune responses against proliferating endothelial cells. In summary, we validated murine endoglin as an effective target for a DNA-based vaccine encoding it which markedly suppresses breast cancer metastases in a prophylactic setting.
Report reveals health inequalities in Wales
Authors: Roger Dobson
Journal: BMJ (1999)

Widespread inequalities in the health of people in Wales have been identified in a new report prepared for the Welsh National Assembly. Areas of the south Wales valleys rank worst on most of the indicators used by the researchers for the 1998 health survey. Rates of heart disease, respiratory illness, mental illness, arthritis, and back problems were all at their highest in the valleys where the population was also the least likely to take weekly exercise or eat green vegetables. The area also had some of the highest smoking rates. The report, based on replies to 50 000 detailed questionnaires sent out to adults by the Welsh Office, found …
Homozygotes carrying an autosomal dominant TIGR mutation do not manifest glaucoma
Authors: Jean Morissette, Christian Clépet, Steve Moisan, Stéphane Dubois, Eric Winstall, Diana Vermeeren, Thai Nguyen, Jon Polansky, Gilles Côté, Jean-Louis Anctil, Marcel Amyot, Micheline Plante, Pierre Falardeau, Vincent Raymond
Journal: Nature Genetics (1998)
Cardiac troponins in chest pain
Authors: G. S Hillis, K. A A Fox
Journal: BMJ (1999)

Despite a fall in the age adjusted prevalence of cardiovascular disease in the developed world,1 the number of patients presenting with chest pain is rising. Greater public awareness of the importance of chest pain has lowered the threshold for seeking medical help, while improvements in our ability to manage acute coronary syndromes necessitate prompt and accurate identification of ischaemic cardiac pain. Most patients who present to accident and emergency departments will have non-cardiac pain and others, with ischaemic pain, will be at low risk of serious adverse events in the short term. In contrast, many of those at high risk have no diagnostic clinical or electrocardiographic findings at presentation (about 50% of patients ultimately diagnosed as having an acute myocardial infarction, and 65% of those with unstable angina, present with non-diagnostic electrocardiograms).2 The major challenge is therefore determining the risk of an individual patient.

There are two components to such risk. “Acute risk” is determined by the volume and severity of ischaemic myocardium (usually reflected in electrocardiographic changes) and the extent of myocardial injury (indicated by troponins and cardiac enzymes). “Prognostic risk” is influenced by prior cardiac damage, confounding …
ACCF/AHA/HFSA 2011 Survey Results: Current Staffing Profile of Heart Failure Programs, Including Programs That Perform Heart Transplant and Mechanical Circulatory Support Device Implantation
Authors: Mariell Jessup, Nancy M. Albert, David E. Lanfear, JoAnn Lindenfeld, Barry M. Massie, Mary Norine Walsh, Mark J. Zucker
Journal: Journal of the American College of Cardiology (2011)
Both Stat5a and Stat5b are required for antigen-induced eosinophil and T-cell recruitment into the tissue
Authors: Shin-ichiro Kagami, Hiroshi Nakajima, Kotaro Kumano, Kotaro Suzuki, Akira Suto, Kazunori Imada, Helen W. Davey, Yasushi Saito, Kiyoshi Takatsu, Warren J. Leonard, Itsuo Iwamoto
Journal: Blood (2000)
Gene Deletion Screen for Cardiomyopathy in Adult Drosophila Identifies Weary (Wry), a New Notch Ligand
Authors: Il-Man Kim
Journal: Circulation (2009)

Abstract #3057 Il-Man Kim, Matthew J. Wolf, Howard A. Rockman, Duke Univ Medical Ctr, Durham, NC Il-Man Kim, 2009 Finalist and Presenting Author
Abstract 14169: Pim-1 Kinase is Required for Endothelial Differentiation of Cardiac Stem Cells via STAT3 Signaling Pathway
Authors: Tomohiko Iwakura, Tomomi Mohri, Tatsuto Hamatani, Tomomi Yamashita, Masanori Obana, Akiko Hayama, Makiko Maeda, Hiroyuki Nakayama, Issei Komuro, Junichi Azuma, Yasushi Fujio
Journal: Circulation (2010)

Background: Cardiac Sca-1+ cells potentially differentiate into cardiac cells, including cardiomyocytes and endothelial cells (ECs). Previously we reported that STAT3 activation by IL-6 family cyto...
Lung function of preschoolers with parapneumonic effusions complicating community acquired pneumonia
Authors: Vasiliki Avramidou, Elpis Hatziagorou, Fotis Kirvassilis, Charalambos Antachopoulos, John Tsanakas
Journal: European Respiratory Journal (2011)

Background: Parapneumonic effusions as a complication of community acquired pneumonia (CAP) in children show an increasing prevalence.

Aim: To monitor expiratory Interrupter Resistance (Rint), Lung Clearance Index (LCI) and chest X-Ray among preschoolers with parapneumonic effusions.

Methods: We evaluated children hospitalized with pleural effusion as a complication of CAP. Expiratory interrupter resistance (Rint) and Lung Clearance Index (LCI) were measured on the day of discharge and six months later.

Results: 13 preschoolers, aged 3.58±1.21 years were studied. In 11/13 (84.6%) Streptococcus Pneumonia was isolated. 84.6% had chest drainage, intrathoracic urokinase was administrated in 69.2% of the children. Two children developed broncho-pleural fistula and one pericarditis. Lung decortication was documented in 1 child. 38.4% of the patients had abnormal chest X-ray, 6 months later. Children with pleural effusions had significantly higher Rint on day of discharge (1.12±0.34 vs 0.78±0.20 kPa L-1 second, p<0.001). Six months later Rint was reduced to normal levels (0.77±0.31 kPa L-1 second, p <0.001). Children with pleural effusion had significantly higher LCI compared to controls (mean difference [95% CI] 2.8 [1.9, 3.8], p<0.001). Six months later, 46.15% of the children had still significantly high LCI, compared to controls [95% CI] 2.2 [1.1, 3.3], p<0.01).

Conclusions: One third of preschoolers with pleural effusions had an abnormal chest X-Ray, while half of the children had significantly high LCI, six months later. LCI is a sensitive marker that detects abnormal lung function and could be used to monitor preschoolers with parapneumonic effusions complicating CAP.
Modernise the NHS in small steps, say experts
Authors: Zosia Kmietowicz
Journal: BMJ (2000)

The best way to expedite the modernisation of the NHS is not by issuing more national directives but by allowing clinicians, nurses, and managers who work together to forge local initiatives that improve the delivery of their services.

Speakers at a forum on quality in health care last week agreed that harnessing local commitment to patients' welfare and encouraging those with new ideas to test them out would drive the new NHS agenda forward.

Hundreds of recommendations on optimal clinical practice are produced by governmental organisations, …
A memorable experience: In the line of duty
Authors: R. N Siddiqui
Journal: BMJ (2000)

Six years ago I was completing the last year of my registrar's rotation in a busy teaching hospital. On-call for general medicine one evening and accompanied by a few final year medical students I could not help noticing a bedraggled young man with wild looking eyes. He was sitting in a cubicle in the accident and emergency department muttering loudly to himself and hopping up and down like a mechanical toy. No, he was not drunk or delirious, I was told; he was a psychiatric patient waiting to be seen. As I …
Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study
Authors: Mark C. Genovese, Roy Fleischmann, Alan J. Kivitz, Maria Rell‐Bakalarska, Renata Martincova, Stefano Fiore, Patricia Rohane, Hubert van Hoogstraten, Anju Garg, Chunpeng Fan, Janet van Adelsberg, Steven P. Weinstein, Neil M. H. Graham, Neil Stahl, George D. Yancopoulos, Tom W. J. Huizinga, Désirée van der Heijde
Journal: Arthritis & Rheumatology (2015)

Objective To evaluate the efficacy and safety of sarilumab in combination with methotrexate (MTX) for the treatment of rheumatoid arthritis (RA). Methods Adults with moderate‐to‐severe RA and an inadequate response to MTX were randomized (1:1:1) to receive sarilumab (doses of 150 mg or 200 mg) or placebo every 2 weeks in conjunction with weekly MTX for 52 weeks. Co–primary end points were the proportion of patients achieving American College of Rheumatology 20% (ACR20) improvement responses at week 24, change from baseline in the Health Assessment Questionnaire (HAQ) disability index (DI) at week 16, and change from baseline in the modified Sharp/van der Heijde score (SHS) of radiographic damage at week 52. Results Baseline characteristics were similar among the groups. For all 3 co–primary end points, the sarilumab 150 mg and 200 mg groups demonstrated statistically significant improvements as compared with the placebo group (ACR20 response rate at week 24, 58.0%, 66.4%, and 33.4%, respectively [ P &lt; 0.0001]; least squares mean change in HAQ DI at week 16, −0.53, −0.55, and −0.29, respectively [ P &lt; 0.0001]; and mean change in SHS at week 52, 0.90, 0.25, and 2.78, respectively [ P &lt; 0.0001]). The most common treatment‐emergent adverse event was infection. In the sarilumab 150 mg, sarilumab 200 mg, and placebo groups, the incidence of serious infections was 2.6%, 4.0%, and 2.3%, respectively. Elevations in alanine aminotransferase levels &gt;3‐fold the upper limit of normal occurred in 9.5%, 8.0%, and 2.1% of patients, respectively; in 24 patients, this led to discontinuation of treatment. Elevated total cholesterol levels were observed in 36.8%, 43.0%, and 18.3% of patients, respectively. In patients receiving 150 mg and 200 mg sarilumab, neutrophil counts of 0.5 to &lt;1.0 × 10 9 /liter were observed in 5.1% and 7.8% of patients, respectively, while neutrophil counts of &lt;0.5 × 10 9 /liter were observed in 0.9% and 0.7% of patients, respectively; none of the patients receiving placebo experienced changes in neutrophil counts. Conclusion In RA patients treated with sarilumab (150 mg or 200 mg every 2 weeks) in combination with MTX, both doses provided sustained clinical efficacy, as shown by significant improvements in symptomatic, functional, and radiographic outcomes. Sarilumab was generally well tolerated. The adverse events observed in this study were consistent with the effects of interleukin‐6 signaling blockade.
Irish government sets up inquiry into retained body organs
Authors: Doug Payne
Journal: BMJ (2000)

The Irish government is setting up an inquiry into the practice of retaining body organs at postmortem examination without the consent of the patient's relatives, following allegations that the procedure was widespread in the 1970s and early 1980s.

The Faculty of Pathology at the Royal College of Physicians of Ireland reacted quickly to revelations concerning organ retention without consent by introducing new postmortem consent procedures last month in which the next of kin can specify which organs can be removed.

Full details on the establishment of the inquiry are expected within days. The minister of health, Michael Martin, wants …
Male Sexual Dysfunction—Reply
Authors: Abraham Morgentaler
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal